



12-02-02

1645 \$

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

DEC 05 2002

TECH CENTER 1600/2900

In Re the Application of:

McKENZIE et al.

Serial No.: 09/163,089

Filed: September 29, 1998

Atty. File No.: 4102-1

For: COMPOSITIONS FOR  
IMMUNOTHERAPY  
AND USES THEREOF

Commissioner for Patents  
Washington, D.C. 20231

Group Art Unit: 1645

Examiner: Zeman, R.

AMENDMENT AND RESPONSE  
(37 CFR 1.116)

"EXPRESS MAIL" MAILING LABEL NUMBER: ev190614489us

DATE OF DEPOSIT: 11/27/02

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE  
"EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE  
UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND  
IS ADDRESSED TO THE COMMISSIONER FOR PATENTS,  
WASHINGTON, D.C. 20231.

TYPED OR PRINTED NAME: Christine Jacquet

SIGNATURE: Christine Jacquet

#26/D  
JM  
~~12/9/02~~  
3/11/03

Dear Sir:

This Amendment and Response is filed in response to a final Office Action having a mailing date of July 29, 2002. Enclosed herewith is a request for a one month extension of time, with the requisite fee, to extend the time for responding from October 29, 2002 to November 29, 2002. No additional fees are believed to be due in connection with this response, but if fees are due, please debit Deposit Account No. 19-1970.

Please amend and reconsider the above-identified application as follows.

IN THE CLAIMS:

Please amend Claim 9 as follows, without prejudice to or disclaimer of the subject matter therein. All other pending claims remain unchanged.

9. (Twice Amended) The composition of Claim 8, wherein said biological response modifiers induce expression of mannose receptors on a cell capable of expressing said mannose receptors.

OK to  
enter  
12/23/02

D

12/04/2002 EHAILE1 00000035 09163089

01 EC+2251

55.00 OP

BEST AVAILABLE COPY